418 related articles for article (PubMed ID: 25773479)
21. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of carvedilol in patients with congestive heart failure.
Nikolic VN; Jankovic SM; Velickovic-Radovanović R; Apostolović S; Stanojevic D; Zivanovic S; Stefanovic N; Pesic S; Jevtovic-Stoimenov T; Djuric J; Markovic V; Milovanovic JR
J Pharm Sci; 2013 Aug; 102(8):2851-8. PubMed ID: 23728853
[TBL] [Abstract][Full Text] [Related]
23. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
Edginton AN; Schmitt W; Willmann S
Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
[TBL] [Abstract][Full Text] [Related]
24. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
Rhee SJ; Chung H; Yi S; Yu KS; Chung JY
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
26. Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations.
Rasool MF; Khalid S; Majeed A; Saeed H; Imran I; Mohany M; Al-Rejaie SS; Alqahtani F
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31694244
[TBL] [Abstract][Full Text] [Related]
27. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
28. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
29. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy.
Kumar A; Choudhary G; Antonio C; Just V; Jain A; Heaney L; Papp MA
Am Heart J; 2001 Sep; 142(3):512-5. PubMed ID: 11526366
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.
Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ
AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362
[TBL] [Abstract][Full Text] [Related]
31. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.
Honda M; Ogura Y; Toyoda W; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
Biol Pharm Bull; 2006 Apr; 29(4):772-8. PubMed ID: 16595916
[TBL] [Abstract][Full Text] [Related]
32. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.
Vogt W
Clin Pharmacokinet; 2014 Jan; 53(1):51-72. PubMed ID: 23839530
[TBL] [Abstract][Full Text] [Related]
33. Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model.
El-Demerdash E; Abdel-Sattar SA; El-Bakly WM; Mohamed EA
Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):767-779. PubMed ID: 28012025
[TBL] [Abstract][Full Text] [Related]
34. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
35. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
[TBL] [Abstract][Full Text] [Related]
36. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
38. The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure.
Aygul N; Ozdemir K; Duzenli MA; Aygul MU
Cardiology; 2009; 112(3):168-73. PubMed ID: 18654081
[TBL] [Abstract][Full Text] [Related]
39. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
[TBL] [Abstract][Full Text] [Related]
40. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Bullinga JR; Alharethi R; Schram MS; Bristow MR; Gilbert EM
J Card Fail; 2005 Dec; 11(9):693-9. PubMed ID: 16360965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
